Aptamers: Prospects in therapeutics and biomedicine

Amy C. Yan, Kathryn M. Bell, Megan M. Breeden, Andrew D. Ellington

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations


Most biopolymer drugs to date have been proteins. However, the ability to select nucleic acid binding species (aptamers) has led to the development of protein inhibitors and modulators that are small, readily synthesized nucleic acids. The techniques for optimizing, stabilizing, and delivering nucleic acid therapies are just beginning to be developed, but the same engineering flexibility that has so far allowed the generation of multiple, high affinity and specificity binding species appears to also apply to the methods for adapting nucleic acids to clinical applications. We review the selection and characterization of various aptamers and their applications to a variety of disease states, and then focus on the hurdles that must be overcome for the use of aptamers as both exogenously delivered drugs and as gene therapies.

Original languageEnglish (US)
Pages (from-to)1802-1827
Number of pages26
JournalFrontiers in Bioscience
Issue number2
StatePublished - 2005
Externally publishedYes


  • Aptamers
  • Gene
  • Gene therapy
  • Review
  • Selex
  • Therapeutics
  • Treatment

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)


Dive into the research topics of 'Aptamers: Prospects in therapeutics and biomedicine'. Together they form a unique fingerprint.

Cite this